Aspirin/lansoprazole

Drug Profile

Aspirin/lansoprazole

Alternative Names: Aspirin/AG-1749; Lansoprazole/aspirin; Takelda; Takepron/low-dose aspirin

Latest Information Update: 13 Jun 2014

Price : $50

At a glance

  • Originator Takeda
  • Class Antiplatelets; Antipyretics; Antiulcers; Benzimidazoles; Gastric antisecretories; Nonsteroidal anti-inflammatories; Pyridines; Salicylic acids; Small molecules; Sulfoxides
  • Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cardiovascular disorders

Most Recent Events

  • 13 Jun 2014 Launched for Cardiovascular disorders (secondary prevention in patients at risk for aspirin-associated gastric ulcers) in Japan (PO)
  • 24 Mar 2014 Registered for Duodenal ulcer (prevention) in Japan (PO)
  • 24 Mar 2014 Registered for Gastric ulcer (prevention) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top